Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: Results of a matched-pair analysis

for Kanto Study Group for Cell Therapy (KSGCT)

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Adult patients with mixed phenotype acute leukemia (MPAL) have a poor prognosis, and the therapeutic role of allogeneic stem cell transplantation (allo-SCT) for MPAL remains to be elucidated. Thus, we retrospectively assessed the efficacy of allo-SCT for MPAL. Eighteen patients with MPAL were identified from the transplant outcome database of Kanto Study Group for Cell Therapy (KSGCT). We also selected 215 patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) as control cohorts using an optimal matching method. The 5-yr overall survival (OS) rate of patients with MPAL was 48.1%, and patients in remission at the time of transplant showed significantly better survival than those not in remission (5-yr OS: 71.8% vs. 0%, P = 0.001). No significant differences were seen in OS when stratifying patients according to immunophenotype, cytogenetic abnormalities, or the type of induction therapy. The 5-yr OS rate of patients with MPAL was not significantly different compared with AML control patients (48.1% vs. 48.1%; P = 0.855) or ALL control patients (48.1% vs. 37.8%; P = 0.426). These results suggested that allo-SCT is an effective treatment for MPAL, especially early in the disease course, and innovative transplant approaches are warranted to improve the transplant outcome of patients with MPAL who are not in remission.

Original languageEnglish
Pages (from-to)455-460
Number of pages6
JournalEuropean Journal of Haematology
Volume95
Issue number5
DOIs
Publication statusPublished - 2015 Nov 1

Fingerprint

Matched-Pair Analysis
Hematopoietic Stem Cell Transplantation
Leukemia
Phenotype
Stem Cell Transplantation
Transplants
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Survival
Survival Rate
Group Psychotherapy
Cell- and Tissue-Based Therapy
Chromosome Aberrations
Therapeutics
Databases

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Matched-pair analysis
  • Mixed phenotype acute leukemia
  • Outcomes
  • Philadelphia chromosome

ASJC Scopus subject areas

  • Hematology

Cite this

Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia : Results of a matched-pair analysis. / for Kanto Study Group for Cell Therapy (KSGCT).

In: European Journal of Haematology, Vol. 95, No. 5, 01.11.2015, p. 455-460.

Research output: Contribution to journalArticle

@article{dec572a9b12c4aaf91c43692114ce729,
title = "Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: Results of a matched-pair analysis",
abstract = "Adult patients with mixed phenotype acute leukemia (MPAL) have a poor prognosis, and the therapeutic role of allogeneic stem cell transplantation (allo-SCT) for MPAL remains to be elucidated. Thus, we retrospectively assessed the efficacy of allo-SCT for MPAL. Eighteen patients with MPAL were identified from the transplant outcome database of Kanto Study Group for Cell Therapy (KSGCT). We also selected 215 patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) as control cohorts using an optimal matching method. The 5-yr overall survival (OS) rate of patients with MPAL was 48.1{\%}, and patients in remission at the time of transplant showed significantly better survival than those not in remission (5-yr OS: 71.8{\%} vs. 0{\%}, P = 0.001). No significant differences were seen in OS when stratifying patients according to immunophenotype, cytogenetic abnormalities, or the type of induction therapy. The 5-yr OS rate of patients with MPAL was not significantly different compared with AML control patients (48.1{\%} vs. 48.1{\%}; P = 0.855) or ALL control patients (48.1{\%} vs. 37.8{\%}; P = 0.426). These results suggested that allo-SCT is an effective treatment for MPAL, especially early in the disease course, and innovative transplant approaches are warranted to improve the transplant outcome of patients with MPAL who are not in remission.",
keywords = "Allogeneic hematopoietic stem cell transplantation, Matched-pair analysis, Mixed phenotype acute leukemia, Outcomes, Philadelphia chromosome",
author = "{for Kanto Study Group for Cell Therapy (KSGCT)} and Hiroaki Shimizu and Takayuki Saitoh and Shinichiro Machida and Shinichi Kako and Noriko Doki and Takehiko Mori and Toru Sakura and Yoshinobu Kanda and Heiwa Kanamori and Shuichi Miyawaki and Shinichiro Okamoto",
year = "2015",
month = "11",
day = "1",
doi = "10.1111/ejh.12516",
language = "English",
volume = "95",
pages = "455--460",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia

T2 - Results of a matched-pair analysis

AU - for Kanto Study Group for Cell Therapy (KSGCT)

AU - Shimizu, Hiroaki

AU - Saitoh, Takayuki

AU - Machida, Shinichiro

AU - Kako, Shinichi

AU - Doki, Noriko

AU - Mori, Takehiko

AU - Sakura, Toru

AU - Kanda, Yoshinobu

AU - Kanamori, Heiwa

AU - Miyawaki, Shuichi

AU - Okamoto, Shinichiro

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Adult patients with mixed phenotype acute leukemia (MPAL) have a poor prognosis, and the therapeutic role of allogeneic stem cell transplantation (allo-SCT) for MPAL remains to be elucidated. Thus, we retrospectively assessed the efficacy of allo-SCT for MPAL. Eighteen patients with MPAL were identified from the transplant outcome database of Kanto Study Group for Cell Therapy (KSGCT). We also selected 215 patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) as control cohorts using an optimal matching method. The 5-yr overall survival (OS) rate of patients with MPAL was 48.1%, and patients in remission at the time of transplant showed significantly better survival than those not in remission (5-yr OS: 71.8% vs. 0%, P = 0.001). No significant differences were seen in OS when stratifying patients according to immunophenotype, cytogenetic abnormalities, or the type of induction therapy. The 5-yr OS rate of patients with MPAL was not significantly different compared with AML control patients (48.1% vs. 48.1%; P = 0.855) or ALL control patients (48.1% vs. 37.8%; P = 0.426). These results suggested that allo-SCT is an effective treatment for MPAL, especially early in the disease course, and innovative transplant approaches are warranted to improve the transplant outcome of patients with MPAL who are not in remission.

AB - Adult patients with mixed phenotype acute leukemia (MPAL) have a poor prognosis, and the therapeutic role of allogeneic stem cell transplantation (allo-SCT) for MPAL remains to be elucidated. Thus, we retrospectively assessed the efficacy of allo-SCT for MPAL. Eighteen patients with MPAL were identified from the transplant outcome database of Kanto Study Group for Cell Therapy (KSGCT). We also selected 215 patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) as control cohorts using an optimal matching method. The 5-yr overall survival (OS) rate of patients with MPAL was 48.1%, and patients in remission at the time of transplant showed significantly better survival than those not in remission (5-yr OS: 71.8% vs. 0%, P = 0.001). No significant differences were seen in OS when stratifying patients according to immunophenotype, cytogenetic abnormalities, or the type of induction therapy. The 5-yr OS rate of patients with MPAL was not significantly different compared with AML control patients (48.1% vs. 48.1%; P = 0.855) or ALL control patients (48.1% vs. 37.8%; P = 0.426). These results suggested that allo-SCT is an effective treatment for MPAL, especially early in the disease course, and innovative transplant approaches are warranted to improve the transplant outcome of patients with MPAL who are not in remission.

KW - Allogeneic hematopoietic stem cell transplantation

KW - Matched-pair analysis

KW - Mixed phenotype acute leukemia

KW - Outcomes

KW - Philadelphia chromosome

UR - http://www.scopus.com/inward/record.url?scp=84944514481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944514481&partnerID=8YFLogxK

U2 - 10.1111/ejh.12516

DO - 10.1111/ejh.12516

M3 - Article

C2 - 25605541

AN - SCOPUS:84944514481

VL - 95

SP - 455

EP - 460

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 5

ER -